Forte Biosciences Inc (FBRX NASDAQ) stock market data APIs
$29.4614
-1.09(-3.7%)
as of December 19, 2025
Try our APIs with
free plan!
Forte Biosciences Inc Financial Data Overview
Price chart is built with
Anychart
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Prev. Close
29.4614
Open
28.371
High
29.8718
Low
25.8696
52 wk Range
4.9-29.71
Market Cap
172 M
Shares Outstanding
12 433 K
EPS
-0.99
Beta
3.296
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Forte Biosciences Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Forte Biosciences Inc data using free add-ons & libraries
Get Forte Biosciences Inc Fundamental Data
Forte Biosciences Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -43 635 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-14
- EPS/Forecast: -0.08
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Forte Biosciences Inc News
New
Forte Biosciences Tops Q2 Loss Forecasts
Key Points GAAP EPS loss of $(0.96) beat analyst expectations for Q2 2025, driven by lower general and administrative expenses. reflecting increased clinical trial activity for lead product FB102. Fo...
Forte Biosciences stock falls after pricing capital raise of $75M via securities offering
Forte Biosciences (NASDAQ:FBRX [https://seekingalpha.com/symbol/FBRX]) has announced the pricing [https://seekingalpha.com/pr/20146901-forte-biosciences-announces-pricing-of-75-million-public-offering...
Forte Biosciences Announces Pricing of $75 Million Public Offering
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a publ...
Forte's celiac disease drug shows positive results in Phase 1b trial
DALLAS - Forte Biosciences, Inc. (NASDAQ:FBRX), a clinical-stage biotech company with a market capitalization of $96.51 million, reported positive data from a Phase 1b trial of its lead drug candidate...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
